{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-002577","form_type":"8-K","ticker":"CVM","cik":"0000725363","company_name":"CEL SCI CORP","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.897204+00:00","generated_at":"2026-06-18T07:55:15.303280+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CEL-SCI Multikine Phase 3 shows 43% survival extension; BLA submission planned","bullets":["Multikine extended overall survival by 43% (HR 0.70; 95% CI 0.49-1.00) vs SOC in 352 LR head & neck cancer patients.","5-year survival: 65.3% Multikine arm vs 49.7% control; benefit increased from 2.8% at 3yr to 15.6% at 5yr.","16.5% of Multikine patients had early tumor response (complete pathological) vs 0% control; responders' death rate 15.6% vs 48.7%.","Data presented at ECHNO 2023; company plans to submit BLA to FDA for newly diagnosed locally advanced SCCHN.","Intended patient population ~210,000 annual global cases; no new approved therapy for decades."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-002577","json":"https://secwatch.observer/filing/0001654954-23-002577.json","markdown":"https://secwatch.observer/filing/0001654954-23-002577.md","text":"https://secwatch.observer/filing/0001654954-23-002577.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/725363/000165495423002577/0001654954-23-002577-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/725363/000165495423002577/cvm_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T07:55:15.303280+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}